International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 553-558 , June 2010

Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria

  • Daria Nicolosi

      Affiliations

    • Department of Microbiological and Gynaecological Sciences, University of Catania, Catania, Italy
    • ,
  • Marina Scalia

      Affiliations

    • Department of Biomedical Sciences, Section of General and Cellular Biology and Molecular Genetics ‘G. Sichel’, University of Catania, Catania, Italy
    • ,
  • Vito M. Nicolosi

      Affiliations

    • Department of Microbiological and Gynaecological Sciences, University of Catania, Catania, Italy
    • Corresponding Author InformationCorresponding author. Present address: Dipartimento di Scienze Microbiologiche e Ginecologiche, via Androne 81, I-95124 Catania, Italy. Tel.: +39 095 250 4712; fax: +39 095 250 4753.
    • ,
  • Rosario Pignatello

      Affiliations

    • Department of Pharmaceutical Sciences, University of Catania, Catania, Italy

Received 29 September 2009 ,Accepted 9 January 2010.

References 

  1. Coates AR, Hu Y. Novel approaches to developing new antibiotics for bacterial infections. Br J Pharmacol. 2007;152:1147–1154
  2. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv. 2008;5:25–44
  3. Yacoby I, Benhar I. Antibacterial nanomedicine. Nanomedicine. 2008;3:329–341
  4. Alipour M, Halwani M, Omri A, Suntres ZE. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int J Pharm. 2008;355:293–298
  5. Goyal P, Goyal K, Vijaya Kumar SG, Singh A, Katare OP, Mishra DN. Liposomal drug delivery systems—clinical applications. Acta Pharm. 2005;55:1–25
  6. Briones E, Colino I, Lanao JM. Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J Control Release. 2008;125:210–227
  7. Carlone NA, Cuffini AM, Tullio V, Cavallo G. Interactions of antibiotics with phagocytes in vitro. J Chemother. 1991;3(Suppl. 1):98–104
  8. Gamazo C, Prior S, Concepción Lecároz M, Vitas AI, Campanaro MA, Pérez G, et al. Biodegradable gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial infections. Expert Opin Drug Deliv. 2007;4:677–688
  9. Pagès JM, James CE, Winterhalter M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol. 2008;6:893–903
  10. James PA, Reeves DS. Bacterial resistance to cephalosporins as a function of outer membrane permeability and access to their target. J Chemother. 1996;8(Suppl. 2):37–47
  11. Hancock REW. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative Gram-negative bacteria. Clin Infect Dis. 1998;27(Suppl. 1):S93–S99
  12. Hancock REW, Brinkman FSL. Function of Pseudomonas porins in uptake and efflux. Annu Rev Microbiol. 2002;56:17–38
  13. Vila J, Martí S, Sánchez-Céspedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother. 2007;59:1210–1215
  14. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother. 2003;51:1109–1117
  15. Vaara M. Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in Gram-negative enteric bacteria. Antimicrob Agents Chemother. 1993;37:354–356
  16. Quintiliani R, Courvalin P. Mechanisms of resistance to antimicrobial agents. In:  Murray PR,  Baron EJ,  Pfaller MA,  Tenover FC,  Yolken RH editor. Manual of clinical microbiology. 6th ed.. Washington, DC: ASM Press; 1995;p. 1319
  17. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342–1347
  18. Reynolds PE, Courvalin P. Vancomycin resistance in enterococci due to synthesis of precursors terminating in d-alanyl-d-serine. Antimicrob Agents Chemother. 2005;49:21–25
  19. Duzgunes N, Nir S. Mechanisms and kinetics of liposome–cell interactions. Adv Drug Deliv Rev. 1999;40:3–18
  20. Goryacheva YA, Vekshina OM, Yashin VA, Kim YA. Fusion and endocytosis of anionic liposomes with Ehrlich ascitic carcinoma cells. Bull Exp Biol Med. 2005;140:733–735
  21. Knoll G, Burger KN, Bron R, van Meer G, Verkleij AJ. Fusion of liposomes with the plasma membrane of epithelial cells: fate of incorporated lipids as followed by freeze fracture and autoradiography of plastic sections. J Cell Biol. 1988;107:2511–2521
  22. Watabe A, Yamaguchi T, Kawanishi T, Uchida E, Eguchi A, Mizuguchi H, et al. Target-cell specificity of fusogenic liposomes: membrane fusion-mediated macromolecule delivery into human blood mononuclear cells. Biochim Biophys Acta. 1999;1416:339–348
  23. Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusogenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA. 1996;93:11421–11425
  24. Goto T, Morishita M, Nishimura K, Nakanishi M, Kato A, Ehara J, et al. Novel mucosal insulin delivery systems based on fusogenic liposomes. Pharm Res. 2006;23:384–391
  25. Kunisawa J, Nakagawa S, Mayumi T. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development. Adv Drug Deliv Rev. 2001;52:177–186
  26. Nakanishi M, Mizuguchi H, Ashihara K, Senda T, Eguchi A, Watabe A, et al. Gene delivery systems using the Sendai virus. Mol Membr Biol. 1999;16:123–127
  27. Boomer JA, Qualls MM, Inerowicz HD, Haynes RH, Patri VS, Kim JM, et al. Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol–vinyl ether–PEG conjugate. Bioconjug Chem. 2009;20:47–59
  28. Karanth H, Murthy RS. pH-sensitive liposomes—principle and application in cancer therapy. J Pharm Pharmacol. 2007;59:469–483
  29. Sakaguchi N, Kojima C, Harada A, Koiwai K, Kono K. The correlation between fusion capability and transfection activity in hybrid complexes of lipoplexes and pH-sensitive liposomes. Biomaterials. 2008;29:4029–4036
  30. Templeton NS. Nonviral delivery for genomic therapy of cancer. World J Surg. 2009;33:685–697
  31. Lasch J, Weissig V, Brandl M. Preparation of liposomes. In:  Torchilin VP,  Weissig V editor. Liposomes—a practical approach. 2nd ed.. Oxford, UK: Oxford University Press; 2003;p. 3–30
  32. Jehl F, Gallion C, Thierry RC, Monteil H. Determination of vancomycin in human serum by high-pressure liquid chromatography. Antimicrob Agents Chemother. 1985;27:503–507
  33. Clinical Laboratory Standards Institute . Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. Document M100-S17. Wayne, PA: CLSI; 2007;
  34. Hope MJ, Nayar R, Mayer LD, Cullis PR. Reduction of liposome size and preparation of unilamellar vesicles by extrusion techniques. In: 2nd ed..  Gregoriadis G editors. Liposome technology. vol. 1:Boca Raton, FL: CRC Press; 1993;p. 123–139
  35. Beaulac C, Sachetelli S, Lagace J. In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against Gram-negative and Gram-positive bacteria. J Antimicrob Chemother. 1998;41:35–41
  36. Guo X, Szoka FC. Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG–diortho ester–lipid conjugate. Bioconjug Chem. 2001;12:291–300
  37. Lubrich B, van Calker D, Peschka-Süss R. Inhibition of inositol uptake in astrocytes by antisense oligonucleotides delivered by pH-sensitive liposomes. Eur J Biochem. 2001;267:2432–2438
  38. Kono K, Iwamoto M, Nishikawa R, Yanagie H, Takagishi T. Design of fusogenic liposomes using a poly(ethylene glycol) derivative having amino groups. J Control Release. 2000;68:225–235
  39. Mok KW, Cullis PR. Structural and fusogenic properties of cationic liposomes in the presence of plasmid DNA. Biophys J. 1997;73:2534–2545
  40. Simões S, Slepushkin V, Düzgünes N, Pedroso de Lima MC. On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochim Biophys Acta. 2001;1515:23–37
  41. Epand RM, Fuller NL, Rand RP. Role of the position of unsaturation on the phase behavior and intrinsic curvature of phosphatidylethanolamines. Biophys J. 1996;71:1806–1810
  42. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis. 2007;26:793–800
  43. Halwani M, Mugabe C, Azghani AO, Lafrenie RM, Kumar A, Omri A. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J Antimicrob Chemother. 2007;60:760–769
  44. Mugabe C, Halwani M, Azghani AO, Lafrenie RM, Omri A. Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:2016–2022
  45. Sachetelli S, Khalil H, Chen T, Beaulac C, Sénéchal S, Lagacé J. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim Biophys Acta. 2000;1463:254–266
  46. Albrecht MC, Griffith ME, Murray CK, Chung KK, Horvath EE, Ward JA, et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg. 2006;203:546–550

PII: S0924-8579(10)00060-9

doi: 10.1016/j.ijantimicag.2010.01.015

International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 553-558 , June 2010

Article Tools

* Image Usage & Resolution